About Medical Institute REAVIZ
Clinical Trials at Medical Institute REAVIZ
During the past decade, Medical Institute REAVIZ conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on
average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Medical Institute REAVIZ
According to Clinical.Site data, the most researched conditions in "Medical Institute REAVIZ" are
"Ulcerative Colitis" (2 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "Medical Institute REAVIZ" in a lesser frequency.
Clinical Trials Intervention Types at Medical Institute REAVIZ
Most popular intervention types in "Medical Institute REAVIZ" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Mirikizumab" (2 trials), "Placebo" (2 trials), "Mirikizumab IV" (1 trials), "Mirikizumab SC" (1 trials) and "Placebo SC" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Medical Institute REAVIZ
The vast majority of trials in "Medical Institute REAVIZ" are
3 trials for "All" genders.
Clinical Trials Status at Medical Institute REAVIZ
Currently, there are NaN active trials in "Medical Institute REAVIZ".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Medical Institute REAVIZ,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Medical Institute REAVIZ, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".